PMC:7228307 / 48031-48625
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
941 | 81-85 | Gene | denotes | HER2 | Gene:2064 | |
942 | 119-123 | Gene | denotes | HER2 | Gene:2064 | |
943 | 240-248 | Gene | denotes | FcγRIIIa | Gene:2214 | |
944 | 326-333 | Gene | denotes | FcγRIIb | Gene:2213 | |
945 | 487-491 | Gene | denotes | HER2 | Gene:13866 | |
946 | 558-562 | Gene | denotes | HER2 | Gene:13866 | |
947 | 368-372 | Gene | denotes | FcγR | Gene:2213 | |
948 | 589-593 | Species | denotes | mice | Tax:10090 | |
949 | 0-12 | Chemical | denotes | Margetuximab | MESH:C000617981 | |
950 | 90-101 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
951 | 428-439 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
952 | 445-457 | Chemical | denotes | margetuximab | MESH:C000617981 | |
953 | 135-142 | Disease | denotes | cancers | MESH:D009369 | |
954 | 574-579 | Disease | denotes | tumor | MESH:D009369 | |
955 | 182-187 | Mutation | denotes | L235V | p.L235V | |
956 | 189-194 | Mutation | denotes | F243L | p.F243L | |
957 | 196-201 | Mutation | denotes | R292P | p.R292P | |
958 | 203-208 | Mutation | denotes | Y300L | p.Y300L | |
959 | 213-218 | Mutation | denotes | P396L | p.P396L |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T390 | 169-180 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T391 | 493-498 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T89 | 19-23 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
T90 | 474-478 | Disease | denotes | ADCC | http://purl.obolibrary.org/obo/MONDO_0008734 |
T91 | 574-579 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T827 | 38-40 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T828 | 240-242 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T829 | 326-328 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T830 | 361-362 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T831 | 368-370 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T832 | 493-507 | http://purl.obolibrary.org/obo/CL_0001034 | denotes | cells in vitro |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T246 | 169-180 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T247 | 169-174 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T248 | 175-180 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T224 | 493-498 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cells |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T53 | 169-180 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
941 | 81-85 | Gene | denotes | HER2 | Gene:2064 | |
942 | 119-123 | Gene | denotes | HER2 | Gene:2064 | |
943 | 240-248 | Gene | denotes | FcγRIIIa | Gene:2214 | |
944 | 326-333 | Gene | denotes | FcγRIIb | Gene:2213 | |
945 | 487-491 | Gene | denotes | HER2 | Gene:13866 | |
946 | 558-562 | Gene | denotes | HER2 | Gene:13866 | |
947 | 368-372 | Gene | denotes | FcγR | Gene:2213 | |
948 | 589-593 | Species | denotes | mice | Tax:10090 | |
949 | 0-12 | Chemical | denotes | Margetuximab | MESH:C000617981 | |
950 | 90-101 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
951 | 428-439 | Chemical | denotes | trastuzumab | MESH:D000068878 | |
952 | 445-457 | Chemical | denotes | margetuximab | MESH:C000617981 | |
953 | 135-142 | Disease | denotes | cancers | MESH:D009369 | |
954 | 574-579 | Disease | denotes | tumor | MESH:D009369 | |
955 | 182-187 | Mutation | denotes | L235V | p.L235V | |
956 | 189-194 | Mutation | denotes | F243L | p.F243L | |
957 | 196-201 | Mutation | denotes | R292P | p.R292P | |
958 | 203-208 | Mutation | denotes | Y300L | p.Y300L | |
959 | 213-218 | Mutation | denotes | P396L | p.P396L |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T46 | 589-593 | Species | denotes | mice | NCBItxid:10095|NCBItxid:10088 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T278 | 0-379 | Sentence | denotes | Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio. |
T279 | 380-594 | Sentence | denotes | This was apparent when compared with unmodified trastuzumab the margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T389 | 169-180 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T390 | 493-498 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T113 | 19-23 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 474-478 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T39 | 574-579 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T35 | 574-579 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T113 | 19-23 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 474-478 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T113 | 19-23 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
T114 | 474-478 | http://purl.obolibrary.org/obo/GO_0001788 | denotes | ADCC |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T278 | 0-379 | Sentence | denotes | Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio. |
T279 | 380-594 | Sentence | denotes | This was apparent when compared with unmodified trastuzumab the margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T35 | 574-579 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |